Status:
COMPLETED
Neuro-orthopaedic Surgery in the Treatment of the Spastic Equinovarus Foot
Lead Sponsor:
University Hospital of Mont-Godinne
Conditions:
Spasticity
Spastic Foot
Eligibility:
All Genders
18-80 years
Brief Summary
Spastic equinovarus foot (SEF) is a major cause of disability in stroke patients. Treatments may include physical therapy, orthosis, botulinum toxin (BTX) injections, selective tibial neurotomy and te...
Detailed Description
INTRODUCTION Stroke is the third cause of death and the leading cause of handicap among industrialized countries (1). Spasticity following stroke is responsible for spastic equinovarus foot (SEF) in ...
Eligibility Criteria
Inclusion
- central neurological disease lasting from more than 6 months
- spastic equinovarus foot due to spasticity and/or contracture
- patient able to walk barefoot
- insufficient benefit from physical therapy and/or orthosis
Exclusion
- pregnant women
- botulinum toxin injection in the last 4 months
- previous surgery for SEF
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01265238
Start Date
December 1 2009
End Date
December 1 2014
Last Update
January 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Mont-Godinne
Yvoir, Belgium, 5530